Travere Therapeutics (TVTX) news
Recent news
Traverse Therapeutics, Inc.: TD Cowen raises target price to $75 from $60
Travere Therapeutics, Inc. (TVTX) has recently seen an upward revision in its price target from TD Cowen, which raised its forecast to $75 per share from a previous $60. This adjustment reflects the firm's updated assessment of the company's growth potential and market positioning. TVTX, a…
AInvest Wire · Aug 5, 2026Traverse Therapeutics Q2 EPS USD -0.37
Travere Therapeutics reported net loss per share of -$0.37 for the second quarter of 2023. The company’s financial results reflect ongoing operational and research expenditures associated with its therapeutic development programs. As of the second quarter, the company continued to allocate…
AInvest Wire · Aug 4, 2026Traverse Therapeutics enters into exclusive licensing agreement with Everest Medicines for CIVOREBRUTINIB a potential best-in-class BTK inhibitor for rare kidney diseases
Travere Therapeutics (NASDAQ: TVTX) has entered into an exclusive licensing agreement with Everest Medicines for CIVOREBRUTINIB, a potential best-in-class Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rare kidney diseases. Under the terms of the agreement, Travere will receive an…
AInvest Wire · Jun 2, 2026Strategy to buyback about $1.50B of conv sr notes due 2029
Travere Therapeutics, Inc. (NASDAQ: TVTX) has priced an upsized offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032, with an option for underwriters to purchase an additional $50.0 million in principal amount to cover over-allotments ( priced an upsized…
AInvest Wire · May 15, 2026Travere successful pre-NDA meeting for Filspari in IgAN; says there is uncertainty around a regulatory path forward for FSGS; implements approximate 20% workforce reduction
AInvest Wire · Dec 4, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.